Form 4: PTC Therapeutics CEO Sells Shares for Tax Obligations

PTC Therapeutics CEO Matthew B. Klein sold 8,089 shares of common stock at $76.64 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Matthew B. Klein, Chief Executive Officer and Director of PTC Therapeutics, Inc. (PTCT), reported a sale of common stock.
• The transaction involved the disposition of 8,089 shares of common stock on December 30, 2025.
• The shares were sold at a price of $76.64 per share.
• The sale was executed automatically pursuant to an irrevocable 'sell to cover' election.
• The purpose of the sale was to satisfy tax withholding obligations associated with the vesting of 18,750 Restricted Stock Units (RSUs).
• These RSUs were part of a larger grant of 75,000 RSUs made on December 28, 2023.
• Following this transaction, Matthew B. Klein beneficially owns 341,875 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, which is a common and pre-planned event for executives. It does not reflect a discretionary sale based on company performance or outlook, thus indicating a neutral sentiment.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it is a report of a past insider transaction.

Industry Context

This filing reports a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The reported transaction is a standard 'sell to cover' to satisfy tax obligations upon RSU vesting, a pre-planned event under a Rule 10b5-1 plan. Such transactions are not indicative of management's view on the company's future performance or a discretionary decision to reduce holdings. Therefore, it does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing fundamentals.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Matthew B. Klein, Corporate Governance